Prescription drug · NDA
Evdi (Trabectedin) NDC 60505-6423
Trabectedin .05 mg/mL · Injection, Solution, Concentrate · Intravenous · Apotex Corp.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60505-6423-0 | 6050564230060505642300 | 1 VIAL, SINGLE-USE in 1 CARTON (60505-6423-0) / 20 mL in 1 VIAL, SINGLE-USEMarketed from Jun 30, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Evdi
- Generic name (nonproprietary)
- trabectedin
- Active ingredients
- Trabectedin — .05 mg/mL
- Dosage form
- Injection, Solution, Concentrate
- Route
- Intravenous
- Labeler
- Apotex Corp.NDC labeler code 60505
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220837
- Marketing start
- Listing expires
- Other FDA classes
- Alkylating Activity (Mechanism)
- Identifiers
- Product ID 60505-6423_63341f3d-2380-37b9-2969-4022718367c9SPL ID 63341f3d-2380-37b9-2969-4022718367c9SPL set ID c1d50f5c-4202-27f3-4798-a9708114ddeaRxCUI 2745754, 2745760UNII ID0YZQ2TCP
- Pharmacologic class
- Alkylating Drug
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N460505642300followed by a unit qualifier and the quantityPackage 60505-6423-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 60505-6423
- What is NDC 60505-6423?
- 60505-6423 is the product NDC for Evdi (trabectedin), Trabectedin .05 mg/mL injection, solution, concentrate, listed with the FDA by Apotex Corp.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Evdi (Trabectedin).
- What is the active ingredient?
- Trabectedin.
- Who is the labeler?
- Apotex Corp., NDC labeler code 60505. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Evdi?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.